Statement from Peter Marks, M.D., Ph.D., Director, FDA’s Center for Biologics Evaluation and Research
The FDA is tasked with taking important steps to respond to the emerging Zika virus outbreak. One of the agency’s key public health responsibilities is to help ensure the safety of the nation’s blood supply.
